AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. .
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca
Resultaten från den svenska SUPPORT-studien, som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt med hjälp av en mobiltelefonapplikation, publiceras nu i American Heart Journal. Studien visar att de patienter som fick ett interaktivt patientverktyg i form av en ”mobil-app” i högre grad tog sitt blodproppshämmande läkemedel ticagrelor enligt läkarens ordination.
73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour types Continued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation, and new data in first-line NSCLC
AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein.
Benralizumab är AstraZenecas första biologiska läkemedel för sjukdomar i andningsvägarna som slutfört studier i fas III
New data reflect advancements across novel inhaled therapies, respiratory biologics and research into underlying disease pathways
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending the approval of a new antibiotic, CAZ AVI 2g/0.5g powder.
Ekonomisk sammanfattning
MUSD Ändring i %
i fasta valutakurser1
Utfall Totala intäkter2
6 115 5 1 Rörelseresultat för kärnverksamheten 3
1 593 (8) (12) Vinst per aktie för kärnverksamheten (Core EPS) $0,95 (7) (12) Redovisat rörelseresultat 1 038 17 11 Redovisad vinst per aktie $0,51 26 17
De total
AstraZeneca today announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of hyperuricemia associated with uncontrolled gout.
Visar på tydlig förbättring i lungfunktion jämfört med monokomponenter och placebo
Den enda långtidsverkande dubbla luftrörsvidgaren som kommer i en dosaerosol (pMDI) och den första produkten med AstraZenecas patenterade Co-Suspension Technology
AstraZeneca meddelar idag att amerikanska Food and Drug Administration har godkänt Bevespi Aerosphere (glykopyrrolat och formoterolfumarat),en inhal
AstraZeneca och MedImmune, koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, meddelar idag ett integrerat forskningsinititativ inom genomik som kommer att ändra vårt sätt att arbeta för att upptäcka och utveckla läkemedel tvärsöver hela forsknings- och utvecklingsportföljen
Phase I first-line Tagrisso (osimertinib) data show an objective response rate of 77%, and progression-free survival of 19.3 months in patients with EGFRm NSCLC1 Updated results in pre-treated patients with EGFR T790M mutation-positive NSCLC further support recent approvals in the US, EU and Japan
More than 60 presentations featuring 26 potential medicines across four key scientific platforms, including DNA Damage Response (DDR) and Immuno-Oncolog
Phase II/III trial of AZD3293, an oral potent small molecule BACE inhibitor, will continue to Phase III after positive interim safety data
Tagrisso™ late-breaker presentations provide updated data in first-line EGFRm and second-line EGFRm T790M lung cancer
Studies demonstrate use of blood based testing to identify patients for treatment with Iressa and Tagrisso
Data from exploratory immuno-oncology and small molecule combination studies to be presented during the conference
AstraZeneca and its global biologics research and
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional approval of Pandemic Live Attenuated Influenza Vaccine (P/LAIV). P/LAIV is indicated for the prevention of influenza in an officially declared pa
First major US guideline to include expanded indication for Brilinta in patients with a heart attack beyond one year